Pipeline

Our pipeline of antibody therapeutics includes investigational medicines in clinical development, and in-house and partnered pre-clinical programs.

Our groundbreaking accomplishments

Approved therapies incorporating �Ǻ�� innovation

Proprietary �Ǻ�� technologies

~20

Products in clinical development incorporating �Ǻ�� innovation

Pipeline as of March 28, 2025

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Oncology

Phase 3

Acasunlimab (GEN1046)

DuoBody^®

Non-small cell lung cancer

Phase 3

Epcoritamab

DuoBody^®

First line diffuse large B-cell lymphoma

Phase 3

Epcoritamab

DuoBody^®

First line follicular lymphoma

Phase 3

Epcoritamab

DuoBody^®

Relapsed or refractory diffuse large B-cell lymphoma

Phase 3

Epcoritamab

DuoBody^®

Relapsed or refractory diffuse large B-cell lymphoma

Phase 3

Epcoritamab

DuoBody^®

Relapsed/refractory follicular lymphoma

Phase 3

Rinatabart sesutecan (Rina-S^®, GEN1184)

Platinum resistant ovarian cancer

Phase 2

Acasunlimab (GEN1046)

DuoBody^®

Non-small cell lung cancer

Phase 2

Epcoritamab

DuoBody^®

B-cell non-Hodgkin lymphoma

Phase 2

Epcoritamab

DuoBody^®

Relapsed/refractory chronic lymphocytic leukemia and Richter’s syndrome

Phase 2

GEN1042/BNT312

DuoBody^®

Solid tumors

Phase 2

Rinatabart sesutecan (Rina-S^®, GEN1184)

Platinum resistant ovarian cancer

Phase 2

Tisotumab vedotin

Solid tumors

Phase 1

Acasunlimab (GEN1046)

DuoBody^®

Solid tumors

Phase 1

Epcoritamab

DuoBody^®

Aggressive mature B-cell neoplasms in pediatric patients

Phase 1

GEN1055/BNT315

HexaBody^®

Solid tumors

Phase 1

GEN1057

DuoBody^®

Solid tumors

Phase 1

GEN1059/BNT314

DuoBody^®

Solid tumors

Phase 1

GEN1107

Solid tumors

Phase 1

GEN1160

Solid and liquid tumors

Phase 1

GEN1286

Solid tumors

Pre-clinical

Multiple active pre clinical programs

Partnered & proprietary programs (DuoBody^®, DuoHexaBody^® and HexaBody^®): Pre-clinical phase

^* Tisotumab vedotin – 50:50 partnership with Pfizer Inc.; DuoBody-CD40x4-1BB 'GEN1059/BNT314 and GEN1055/BNT315' – 50:50 partnership with BioNTech; Epcoritamab – 50:50 partnership with AbbVie Inc.

^** Out-licensed products marketed by partner.

^*** Products under development by a third-party incorporating �Ǻ�� technology and innovation.

This overview of our clinical development programs is updated quarterly. Changes that occurred in our pipeline are detailed in our .

COM-GL-Pipeline-0000045

Explore further

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Daratumumab

Partner: Janssen Biotech, Inc.

Ofatumumab

Partner: Novartis Pharma AG

Teprotumumab

Partner: Horizon Therapeutics, under a license from Roche

^** Out-licensed products marketed by partner.

^*** Products under development by a third-party incorporating �Ǻ�� technology and innovation.

This overview of our clinical development programs is updated quarterly. Changes that occurred in our pipeline are detailed in our .

COM-GL-Pipeline-0000045

Explore further

The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established.

Amivantamab

Partner: Janssen Biotech, Inc.

Camidanlumab tesirine

Partner: ADC Therapeutics

Inclacumab

Partner: Pfizer

Lu AF82422

Partner: H. Lundbeck A/S

Mim8

Partner: Novo Nordisk

Ordesekimab

Partner: Provention Bio

Talquetamab (JNJ-64407564)

Partner: Janssen Biotech, Inc.

Teclistamab (JNJ-64007957)

Partner: Janssen Biotech, Inc.

^** Out-licensed products marketed by partner.

^*** Products under development by a third-party incorporating �Ǻ�� technology and innovation.

This overview of our clinical development programs is updated quarterly. Changes that occurred in our pipeline are detailed in our .

COM-GL-Pipeline-0000045

Explore further

�Ǻ�����

�Ǻ��